Skip to Content

  • Search

View Additional Section Content

A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P07037

Principal Investigator(s)
David Weisman, M.D.
Brad Klein, M.D. (Sub-Investigator)
Lee Harris, M.D. (Sub-Investigator)
Dan J. Gzesh, M.D. (Sub-Investigator)
John Khoury, M.D. (Sub-Investigator)

Clinical Trial Categories

  • Parkinson’s Disease
Jennifer McGowan at 215-327-0161


  • Abington Neurological Associates, Ltd

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details